Skip to main content

Table 3 Patient demographics, disease activity, and functional and structural characteristics according to serological status of RF and ACPA: golimumab database

From: Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials

 

Patient subgroups according to autoantibody status

P values of direct group comparisons

 

(1) RF−/ACPA−

(2) RF−/ACPA+

(3) RF+/ACPA−

(4) RF+/ACPA+

Overall

Pairwise comparisons

Patients, number

268

68

93

937

0.48

Not done

Age, years

51.7 (12.8)

48.1 (14.4)

52.2 (12.0)

51.2 (11.9)

0.15

Not done

Disease duration, years

6.8 (8.5)

4.9 (5.7)

6.4 (6.9)

7.8 (8.2)

<0.001

(1) vs. (4)**; (2) vs. (4)***

Female, %

82.1

80.9

86.0

81.4

0.74

Not done

Rheumatoid factor

9.3 (2.8)

10.8 (2.6)

96 (162)

190 (275)

n.d.

Not done

ACPA

2.1 (0.4)

112 (167)

2.5 (0.9)

225 (409)

n.d.

Not done

Health assessment questionnaire

1.5 (0.6)

1.3 (0.7)

1.4 (0.7)

1.5 (0.7)

0.02

(1) vs. (2)*; (2) vs. (4)*

Disease activity score 28 (ESR)

5.6 (1.0)

5.1 (1.1)

5.6 (0.8)

5.5 (1)

0.06

Not done

Disease activity score 28 (CRP)

5.1 (1.0)

4.7 (1.0)

5.1 (1.0)

5.1 (1)

0.007

(1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)**

Simplified disease activity index

40.7 (14.8)

33.4 (12.4)

40.0 (16.3)

39.3 (14.3)

0.002

(1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)***

Clinical disease activity index

38.7 (14.1)

31.7 (12.2)

37.6 (14.9)

37.1 (13.4)

0.002

(1) vs. (2)***; (2) vs. (3)*; (2) vs. (4)***

Swollen joint count

10.7 (6.4)

8.7 (4.7)

10.9 (6.4)

10.7 (5.9)

0.06

Not done

Tender joint count

15.7 (7.9)

11.9 (6.9)

15.1 (8.0)

14.3 (7.2)

0.001

(1) vs. (2)***; (1) vs. (4)**; (2) vs. (3)*; (2) vs. (4)**

Pain (VAS)

65.2 (19.5)

61.1 (25.0)

60.4 (23.6)

62.7 (22.3)

0.41

Not done

Patient global assessment (VAS)

62.2 (22.1)

57.0 (25.0)

59.3 (24.7)

59.9 (23.5)

0.43

Not done

Evaluator global assessment (VAS)

60.7 (17.4)

53.6 (19.1)

57 (18.1)

61.5 (17.6)

0.003

(1) vs. (2)**; (3) vs. (4)*; (2) vs. (4)**

Erythrocyte sedimentation rate

37.1 (25.7)

38.0 (22.7)

40.1 (26.4)

42.8 (26.8)

0.08

Not done

C-reactive protein

1.9 (2.8)

1.8 (2.5)

2.3 (4.4)

2.2 (2.7)

<0.001

(1) vs. (4)***; (3) vs. (4)*; (2) vs. (4)*

Radiographic score

15 (26)

24.3 (47.2)

18.3 (31.7)

29.6 (44.9)

<0.001

(1) vs. (4)***; (3) vs. (4)*

  1. n.d. not determined, ACPA antibody against citrullinated proteins, ESR erythrocyte sedimentation rate, CRP C-reactive protein, VAS visual analogue scale
  2. *P < 0.05; **P < 0.01; ***P < 0.001; bold P-values indicate significance at the <0.05 level. For these variables pairwise comparisons ensued
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us